Risperidone and Olanzapine
ApprovedSmall molecule
Risperidone and Olanzapine is one of 16 small molecule programs targeting Parkinsonism. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Parkinsonism
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Northera
LundbeckPhase 2
Kynmobi
SSamson Clinical Operations Pty Ltd
Phase 2
Trental
VValidus Pharmaceuticals
Phase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Carbidopa-Levodopa
Neurocrine BiosciencesPhase 2
Risperidone and Olanzapine
TTaoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Approved
F-18
BayerPhase 2
Incobotulinum Toxin a
NNorthwestern University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Risperidone and Olanzapine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details